Labcorp Holdings (LH) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $4.78
- Estimate
- $4.64
- Surprise
- +2.9%
- Revenue (period 2026-09-30)
- $3.81B
- Score at report (before → after)
- 5.7 → 5.8/10
Revenue source: xbrl.
How the report landed
Labcorp Holdings (LH) beat the $4.64 estimate with adjusted EPS of $4.78 — a modest 2.9% upside surprise. TrendMatrix's engine moved from Buy (Wait) (5.7/10) to Hold at 5.8/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates LH Sell at 5.0/10.
4 of the last 4 quarters beat the estimate; this quarter's +2.9% surprise compares with a +3.5% four-quarter average. Next scheduled report: 2027-02-23.
What supports the rating
- Strong earnings beat streak (4/4)
What argues against it
- Concentration risk — Product: Dx segment (78.0%)
- Concentration risk — Geographic: North America (87.0%)
- Analyst target reached - limited upside remaining
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $369.12
- Stop
- $351.60
The stock trades at 30.2× trailing but 18.8× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-11-18 — shown for context, not personalized investment advice.
LH at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Diagnostics & Research
- Market cap
- $29.90B
- P/E (fwd)
- 18.8
- P/E (ttm)
- 30.2
- 52-week range
- $245.00–$375.10
- Off 52-week high
- 1.6%
- RSI (14)
- 51
- Volume vs avg
- 0.35×
- Score today
- 5.0/10